Effectiveness of the 23-valent polysaccharide pneumococcal vaccine against invasive pneumococcal disease in people 60 years or older

被引：0
|
作者：
Angel Vila-Corcoles
Olga Ochoa-Gondar
Jorge A Guzmán
Teresa Rodriguez-Blanco
Elisabet Salsench
Cruz M Fuentes
机构：
[1] Institut Catalá de la Salut,Primary Care Service of Tarragona
[2] IDIAP Jordi Gol Foundation,Valls
[3] Rovira i Virgili University,Department of Epidemiology and Biostatistics
来源：
BMC Infectious Diseases | / 10卷
关键词：
Influenza; Risk Stratum; Influenza Vaccination; Vaccine Effectiveness; Invasive Pneumococcal Disease;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [31] The Impact of 7-valent Pneumococcal Conjugate Vaccine on Invasive Pneumococcal Disease: A Literature Review
    Myint, Tin Tin Htar
    Madhava, Harish
    Balmer, Paul
    Christopoulou, Dina
    Attal, Sepideh
    Menegas, Damianos
    Sprenger, Ralf
    Bonnet, Eric
    ADVANCES IN THERAPY, 2013, 30 (02) : 127 - 151
  • [32] Infants at Risk for Invasive Pneumococcal Disease in the 13-Valent Pneumococcal Conjugate Vaccine Era
    Yildirim, Inci
    Pelton, Stephen I.
    CLINICAL INFECTIOUS DISEASES, 2019, 69 (01) : 91 - 92
  • [33] Effectiveness of 23-valent pneumococcal polysaccharide vaccination in preventing community-acquired pneumonia hospitalization and severe outcomes in the elderly in Spain
    Dominguez, Angela
    Soldevila, Nuria
    Toledo, Diana
    Torner, Nuria
    Force, Luis
    Jose Perez, Maria
    Martin, Vicente
    Rodriguez-Rojas, Lourdes
    Astray, Jenaro
    Egurrola, Mikel
    Sanz, Francisco
    Castilla, Jesus
    PLOS ONE, 2017, 12 (02):
  • [34] Prevention of Invasive Pneumococcal Disease: Problems Emerged After Some Years of the 13-Valent Pneumococcal Conjugate Vaccine Use
    Nicola Principi
    Giuseppe Di Cara
    Ilaria Bizzarri
    Chiara Isidori
    Paola Borgia
    Costanza Mignini
    Marco Saponara
    Alberto Argentiero
    Susanna Esposito
    Current Infectious Disease Reports, 2018, 20
  • [35] Prevention of Invasive Pneumococcal Disease: Problems Emerged After Some Years of the 13-Valent Pneumococcal Conjugate Vaccine Use
    Principi, Nicola
    Di Cara, Giuseppe
    Bizzarri, Ilaria
    Isidori, Chiara
    Borgia, Paola
    Mignini, Costanza
    Saponara, Marco
    Argentiero, Alberto
    Esposito, Susanna
    CURRENT INFECTIOUS DISEASE REPORTS, 2018, 20 (01)
  • [36] Post-licensure safety surveillance of 23-valent pneumococcal polysaccharide vaccine in the Vaccine Adverse Event Reporting System (VAERS), 1990-2013
    Miller, Elaine R.
    Moro, Pedro L.
    Cano, Maria
    Lewis, Paige
    Bryant-Genevier, Marthe
    Shimabukuro, Tom T.
    VACCINE, 2016, 34 (25) : 2841 - 2846
  • [37] Impact of the 13-Valent Pneumococcal Conjugate Vaccine on Invasive Pneumococcal Disease After Introduction Into Routine Pediatric Use
    Baxter, Roger
    Aukes, Laurie
    Pelton, Stephen, I
    Yee, Arnold
    Klein, Nicola P.
    Gruber, William C.
    Scott, Daniel A.
    Center, Kimberly J.
    JOURNAL OF THE PEDIATRIC INFECTIOUS DISEASES SOCIETY, 2021, 10 (02) : 141 - 150
  • [38] Imputing the Direct and Indirect Effectiveness of Childhood Pneumococcal Conjugate Vaccine Against Invasive Pneumococcal Disease by Surveying Temporal Changes in Nasopharyngeal Pneumococcal Colonization
    Nzenze, Susan A.
    Madhi, Shabir A.
    Shiri, Tinevimbo
    Klugman, Keith P.
    de Gouveia, Linda
    Moore, David P.
    Karstaedt, Alan S.
    Tempia, Stefano
    Nunes, Marta C.
    von Gottberg, Anne
    AMERICAN JOURNAL OF EPIDEMIOLOGY, 2017, 186 (04) : 435 - 444
  • [39] Changes in Invasive Pneumococcal Disease Spectrum After 13-Valent Pneumococcal Conjugate Vaccine Implementation
    Levy, Corinne
    Varon, Emmanuelle
    Ouldali, Naim
    Bechet, Stephane
    Bonacorsi, Stephane
    Cohen, Robert
    CLINICAL INFECTIOUS DISEASES, 2020, 70 (03) : 446 - 454
  • [40] Mortality of Invasive Pneumococcal Disease following Introduction of the 13-Valent Pneumococcal Conjugate Vaccine in Greenland
    Alexandrova Nikolova, Kristiana
    Andersson, Mikael
    Slotved, Hans-Christian
    Koch, Anders
    VACCINES, 2024, 12 (02)
12345